Eslicarbazepine Acetate
- 醋酸艾司利卡西平；BIA 2-093
货号： abs816083
| 货号-规格 | 货期 | 价格 | 数量 |
| abs816083-10mg | 1-2周 | ￥552.00 | - + |
| abs816083-20mg | 1-2周 | ￥964.00 | - + |
| abs816083-100mg | 1-2周 | ￥2048.00 | - + |
大包装询价| 产品描述 | ||
| 描述 | Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. | |
| 纯度 | 99% | |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. | |
| 基本信息 | ||
| 别名 | 醋酸艾司利卡西平；BIA 2-093 | |
| 外观 | 白色固体 | |
| 可溶性/溶解性 | DMSO : 55 mg/mL (185.6 mM) Ethanol : 9 mg/mL (30.4 mM) | |
| 生物活性 | ||
| 靶点 | Beta-secretase | |
| In vivo(体内研究) | Eslicarbazepine acetate is an antiepileptic drug. It is a prodrug which is activated to eslicarbazepine (S-licarbazepine), an active metabolite of oxcarbazepine. Eslicarbazepine acetate is a prodrug for (S)-(+)-licarbazepine, the major active metabolite of oxcarbazepine. Its mechanism of action is therefore identical to that of oxcarbazepine. Eslicarbazepine acetate may not produce as high peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine which could theoretically improve tolerability. | |
| 参考文献 | ||
| 参考文献 | ||
| 温馨提示：本产品仅作科研实验使用，不支持临床等研究 |
- 实验方法 实验条件
共 0 张，还能上传 8 张 提交
- 提示： 尊敬的客户您好，如果您对我们的产品有什么疑问或想要了解的，可以点击“我要咨询”按钮填写您的疑问。
提交不成功？请联系info@absin.cn。
Certificate of Analysis(COA)
促销资讯 更多
订购信息
您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商，请从以下的下拉列表中选择。
危险品化学品经营许可证(不带存储) 许可证编号：沪(浦)应急管危经许[2022]202585(YS)
营业执照(三证合一)